Genomic analyses identify molecular subtypes of pancreatic cancer
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS G12D mutations are most commonly observed in pancreatic ductal adenocarcinoma (36%, [20]) and colorectal cancers (12%, [21]) and are also found in lung, endometrial and other cancers.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [20]
In the citing paper
“Importantly, a study conducted genomic analyses on pancreatic cancer, involving 456 tumors primarily of PDAC and its variants. The research identified 32 significantly mutated genes grouped into 10 molecular mechanisms, including KRAS mutations in 92% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [87]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [11]
In the citing paper
“Amongst these are four canonical mutations – KRAS (~85%), TP53 (60–70%), CDKN2A (>50%), and SMAD4 (~50%).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [51]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Cited by
Items 701–800 of 1,020
Chen, Y., Wen, Y., Xie, C., Chen, X., He, S., Bo, X., & Zhang, Z. (2023) · iScience · doi:10.1016/j.isci.2023.107378 · Cited by 61
“2 At present, the identification of cancer subtypes has shifted from traditional morphological subtyping to molecular subtyping which is more precise.”
BackgroundPCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer
Rademaker, G., Hernandez, G. A., Seo, Y., Dahal, S., Miller‐Phillips, L., Li, A. L., Peng, X. L., Luan, C., Qiu, L., Liegeois, M. A., et al. (2025) · Nature · doi:10.1038/s41586-025-09017-8 · Cited by 73
“Prior transcriptional profiling studies have shown that PDAC can be stratified into two main transcriptional subtypes termed ‘basal’ and ‘classical’, which are linked to distinct molecular features and patient prognosis 17–21 .”
Henriksen, S. D., Madsen, P. H., Larsen, A. C., Johansen, M. B., Pedersen, I. S., Krarup, H. B., & Thorlacius‐Ussing, O. (2017) · Oncotarget · doi:10.18632/oncotarget.21397 · Cited by 56
“This intra-stage variance might reflect different tumor biology, caused by various gene expression profiles [4].”
BackgroundGenomics of adult and pediatric solid tumors.
Rahal, Z., Abdulhai, F., Kadara, H. N., & Saab, R. H. (2018) · Europe PMC (PubMed Central) · Cited by 58
Lundgren, S., Elebro, J., Heby, M., Nodin, B., Leandersson, K., Micke, P., Jirström, K., & Mezheyeuski, A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32945 · Cited by 57
“19,20 Hence, a deeper understanding of the multifaceted role of different immune cell populations in pancreatic and per-iampullary adenocarcinomas is needed.”
Gebregiworgis, T., Kano, Y., St-Germain, J., Radulovich, N., Udaskin, M. L., Mentes, A., Huang, R., Poon, B. P. K., He, W., Valencia-Sama, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26526-y · Cited by 49
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodMolecular Subtyping and Precision Medicine for Pancreatic Cancer
Froeling, F. E. M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K.-F., & Precision-Panc, O. B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010149 · Cited by 54
“With the increase in genomic data over time, other genes that mutate at a frequency of 5–10% have been identified, including many epigenetic regulators, such as KDM6A, MLL3 and ARID1A, but most mutations occur at a prevalence of 5%, with a median of 1% [15,19].”
BackgroundMethodInfluentialSelf-citationTraub, B., Link, K. H., & Kornmann, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.030 · Cited by 57
Heritable defects in telomere and mitotic function selectively predispose to sarcomas
Ballinger, M. L., Pattnaik, S., Mundra, P. A., Zaheed, M., Rath, E. M., Priestley, P., Baber, J., Ray-Coquard, I. L., Isambert, N., Causeret, S., et al. (2023) · Science · doi:10.1126/science.abj4784 · Cited by 58
Self-citationMaurin, M. M., Ranjouri, M., Megino‐Luque, C., Newberg, J. Y., Du, D., Martin, K., Miner, R. E., Prater, M. S., Wee, D. K. B., Centeno, B. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44126-w · Cited by 57
“These data con fi rm the observed increase in RBFOX2 in the squamous sub-type of PDAC reported by Bailey et al. 31 .”
Reese, K.-L., Pantel, K., & Smit, D. J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03166-w · Cited by 62
“Analysis of genomic aberrations in all-stages PDAC tissue revealed a panel of four genes, namely, KRAS , CDKN2A , TP53, and SMAD4, with mutation frequencies of 90%, 90%, 70%, and 55%, respectively, as the main genomic drivers of PDAC [57–61].”
BackgroundCirculating tumor DNA as a liquid biopsy target for detection of pancreatic cancer
Takai, E., & Yachida, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i38.8480 · Cited by 56
Colorectal cancer subtypes: Translation to routine clinical pathology
Roseweir, A. K., McMillan, D. C., Horgan, P. G., & Edwards, J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.006 · Cited by 60
“19 (PDAC), RNA-seq analysis of 232 tumours has revealed four subtypes [61], and for lung cancer, whole genome sequencing of 230 tumours also revealed four distinct subtypes [62].”
BackgroundLiu, B., Yang, H., Taher, L., Denz, A., Grützmann, R., Pilarsky, C. P., & Weber, G. F. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.03.003 · Cited by 62
“NR5A2 has been reported to be upregulated in pancreatic cancer [45]; ECT2, NRP2, and TGFBI are novel candidates.”
BackgroundSelf-citationMcl‐1 targeting could be an intriguing perspective to cure cancer
Blasio, A. D., Vento, R., & Fiore, R. D. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26786 · Cited by 59
“The PDA development is the result of the accumulation of morphological and genetic alterations, and most patients succumb with disease progression (Bailey et al., 2016; Xu, Pothula, Wilson, & Apte, 2014).”
BackgroundTissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy
Nelson, B. S., Lin, L., Kremer, D. M., Sousa, C. M., Cotta‐Ramusino, C., Myers, A. L., Ramos, J., Gao, T., Kovalenko, I., Wilder-Romans, K., et al. (2020) · Cancer & Metabolism · doi:10.1186/s40170-019-0202-2 · Cited by 56
Li, S., Lavrijsen, M., Bakker, A., Magierowski, M., Magierowska, K., Liu, P., Wang, W., Peppelenbosch, M. P., & Smits, R. (2020) · Oncogene · doi:10.1038/s41388-020-1232-5 · Cited by 50
Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells
Galenkamp, K. M. O., Sosicka, P., Jung, M., Recouvreux, M. V., Zhang, Y., Moldenhauer, M. R., Brandi, G., Freeze, H. H., & Commisso, C. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1007 · Cited by 61
Sunami, Y., Boeker, V., & Kleeff, J. H. (2021) · Cancers · doi:10.3390/cancers13040697 · Cited by 59
“It has been shown that patients with the squamous subtype have shorter median survival [83].”
BackgroundEyres, M., Lanfredini, S., Xu, H., Burns, A., Blake, A., Willenbrock, F. W., Goldin, R. D., Hughes, D. L., Hughes, S. L., Thapa, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.044 · Cited by 51
Khouzam, R. A., Rao, R. S. P., Venkatesh, G. H., Zeinelabdin, N. A., Buart, S., Meylan, M., Nimmakayalu, M. A., Terry, S., & Chouaïb, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680435 · Cited by 57
“In this setting, hypoxia was found to dominate in the subtypes with worse prognosis (9, 20, 38).”
BackgroundBenzel, J., & Fendrich, V. (2018) · Oncology Research and Treatment · doi:10.1159/000493473 · Cited by 64
Three hypomethylated genes were associated with poor overall survival in pancreatic cancer patients
Chen, H.-M., Kong, Y., Yao, Q., Zhang, X., Fu, Y., Li, J., Liu, C., & Wang, Z. (2019) · Aging · doi:10.18632/aging.101785 · Cited by 49
HDAC2 Facilitates Pancreatic Cancer Metastasis
Krauß, L., Urban, B. C., Hastreiter, S., Schneider, C., Wenzel, P., Hassan, Z., Wirth, M., Lankes, K., Terrasi, A., Klement, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3209 · Cited by 55
“Mutational inactivation of the TGF pathway, most frequently by alterations of SMAD4, occurs in approximately one half of PDACs (58,59).”
Annual review of KRAS inhibitors in 2022
Wang, H., Chi, L., Yu, F., Dai, H., Gao, C., Si, X., Wang, Z., Liu, L., Zheng, J., Shan, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115124 · Cited by 57
Mercanti, L., Sindaco, M., Mazzone, M., Marcantonio, M. C. D., Piscione, M., Muraro, R., & Mincione, G. (2023) · Cancers · doi:10.3390/cancers15112923 · Cited by 62
Carlo, S. E. D., Raffenne, J., Varet, H., Ode, A., Granados, D. C., Stein, M., Legendre, R., Tuckermann, J. P., Bousquet, C., & Peduto, L. (2023) · Nature Immunology · doi:10.1038/s41590-023-01642-7 · Cited by 56
“We also selected one International Cancer Genome Consortium (ICGC) project, pancreatic ductal adenocarcinoma (PACA_AU, array-based analysis), retrieved from Bailey et al. 83 .”
MethodTargeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Linehan, A., O’Reilly, M., McDermott, R., & O'Kane, G. M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1369136 · Cited by 60
“KRAS Q61H is found in about 5% of pancreatic cancer and is selectively associated with increased survival (20, 21).”
BackgroundDrosos, Y., Escobar, D., Chiang, M.-Y., Roys, K., Valentine, V. A., Valentine, M. B., Rehg, J. E., Sahai, V., Begley, L., Ye, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11661-8 · Cited by 54
Epithelial-Stromal Interactions in Pancreatic Cancer
Zhang, Y., Crawford, H. C., & Pasca di Magliano, M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114515 · Cited by 49
Mechanisms and pathways of mitochondrial outer membrane protein biogenesis
Gupta, A., & Becker, T. (2020) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2020.148323 · Cited by 54
Arid1a restrains Kras-dependent changes in acinar cell identity
Livshits, G., Alonso-Curbelo, D., Morris, J. P., Koche, R., Saborowski, M., Wilkinson, J. E., & Lowe, S. W. (2018) · eLife · doi:10.7554/elife.35216 · Cited by 48
Pishvaian, M. J., Wang, H., He, A. R., Hwang, J. J., Smaglo, B. G., Kim, S. S., Weinberg, B. A., Weiner, L. M., Marshall, J. L., & Brody, J. R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1301 · Cited by 48
“Anemia 6 (9) 2 (3) 4 (6) 4 (13) 1 (3) 3 (10) 1 (6) 1 (6) 1 (7) 1 (7)”
InfluentialTargeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184351 · Cited by 53
“Patients with KRASG12C mutation (1% in patients with PDAC) [18] are sensitive to KRASG12C inhibitors [19–22], and those with the neurotrophic receptor tyrosine kinase (NTRK) gene fusion (0.”
BackgroundPancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
Taherian, M., Wang, H., & Wang, H. (2022) · Cells · doi:10.3390/cells11193068 · Cited by 67
“The immunogenic subtype (29%) contained a family of genes related to immune cell function including B cell signaling, Toll-like receptor signaling, antigen presentation, and the infiltration of CD8+ and CD4+ T cells, with the upregulation of the immune inhibitor PD-1 and cytotoxic T-lymphocyte-associated protein-4 (CT…”
BackgroundInfluentialTumor-Specific CD4 T Cells Instruct Monocyte Differentiation in Pancreatic Ductal Adenocarcinoma
Patterson, M. T., Burrack, A. L., Xu, Y., Hickok, G. H., Schmiechen, Z. C., Becker, S., Cruz-Hinojoza, E., Schrank, P. R., Kennedy, A. E., Firulyova, M. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2023.112732 · Cited by 51
“These data are consistent with an immunogenic subtype that constitutes a large fraction of the patient population.(18) TAMs are diverse and participate in complex processes, including angiogenesis, metastasis, and inflammation.”
Philip, P. A., Sahai, V., Bahary, N., Mahipal, A., Kasi, A., Lima, C. M. S. R., Alistar, A. T., Oberstein, P. E., Golan, T., Metges, J., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02659 · Cited by 61
“22 Despite this relative genomic homogeneity, different subtypes of PC on the basis of gene expression pro fi ling have been described 23-25 ; FFX appears to have no major antitumor effect in the basal subtype in the COMPASS study.”
Germline mutations in pancreatic cancer and potential new therapeutic options
Pihlak, R., Valle, J. W., & McNamara, M. G. (2017) · Oncotarget · doi:10.18632/oncotarget.17291 · Cited by 53
“They further categorised their results to describe four pancreatic cancer subtypes: squamous, pancreatic progenitor, immunogenic and aberrantly differentiated endocrine exocrine (ADEX) [52], and although these aSubset of patients who pursued genetic testing. bOnly Jewish patients with PDAC. cOut of 421 patients, 389 h…”
BackgroundTargeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer
Berger, A. W., Schwerdel, D., Ettrich, T. J., Hann, A., Schmidt, S. A., Kleger, A., Marienfeld, R. B., & Seufferlein, T. T. W. (2017) · Oncotarget · doi:10.18632/oncotarget.23330 · Cited by 48
Hata, T., Suenaga, M., Marchionni, L., Macgregor-Das, A. M., Yu, J., Shindo, K., Tamura, K., Hruban, R. H., & Goggins, M. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.03.012 · Cited by 50
Self-citationRoles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer
Jin, W. (2020) · Cancers · doi:10.3390/cancers12010147 · Cited by 52
“(B) The overall frequency of mutated TrkC in ancer types. cSCC [50], DM [51], CM: T GA Dataset, BC : [52], LA: [53], EC: T GA Dataset, VV-SCC: [54], NSCLC: [55], UTU [56], CTCL: [57], AS: TCGA Dataset, CRC: 8 GC Dataset, CSC : TCGA Dataset, EAC: [59], HNC: TCGA Dataset, RMS: [60], PAC: [61], DLBCL: TCGA Dataset, HCC:…”
InfluentialHuang, B., Trujillo, M. A. M., Fujikura, K., Qiu, M., Chen, F., Felsenstein, M., Zhou, C., Skaro, M. F., Gauthier, C. D., Macgregor‐Das, A. M., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5515 · Cited by 52
Self-citationGonzález, R. S., Raza, A., Propst, R., Adeyi, O. A., Bateman, J., Sopha, S. C., Shaw, J. C., & Auerbach, A. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0047-ra · Cited by 55
Duan, K., Jang, G.-H., Grant, R. C., Wilson, J. M., Notta, F., O'Kane, G. M., Knox, J. J., Gallinger, S., & Fischer, S. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-94544-3 · Cited by 51
Martínez‐Bosch, N., Cristóbal, H., Iglesias, M., Gironella, M., Barranco, L., Visa, L., Calafato, D., Jiménez-Parrado, S., Earl, J., Carrato, A., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103797 · Cited by 50
Sadozai, H., Acharjee, A., Eppenberger‐Castori, S., Gloor, B., Gruber, T., Schenk, M., & Karamitopoulou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643529 · Cited by 55
The role of tumor heterogeneity in immune-tumor interactions
Knoche, S. M., Larson, A. C., Sliker, B. H., Poelaert, B. J., & Solheim, J. C. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09957-3 · Cited by 51
Hosen, S. M. Z., Uddin, M. N., Xu, Z., Buckley, B. J., Perera, C. J., Pang, T., Mekapogu, A. R., Moni, M. A., Notta, F., Gallinger, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1060957 · Cited by 60
“For the ICGC-Pancreatic Cancer - Australia (ICGC-PACA-AU) cohort, data were obtained from the Supplementary Material of the corresponding publication (4).”
BackgroundMethodDriver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression
Bailey, P. J., Ridgway, R. A., Cammareri, P., Treanor-Taylor, M., Bailey, U., Schoenherr, C., Bone, M., Schreyer, D., Purdie, K. J., Thomson, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40822-9 · Cited by 52
“Human RNA sequencing analysis was performed as previously described 52 .”
MethodSelf-citationNusrat, F., Khanna, A., Jain, A., Jiang, W., Lavu, H., Yeo, C. J., Bowne, W. B., & Nevler, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072103 · Cited by 60
“Furthermore, their re-examination of the Biankin dataset [5] suggested that tumors with low mutant allele frequency, when corrected for tumor cellularity, are possibly associated with better survival outcomes (though they failed to reach statistical significance in their analysis).”
BackgroundMTOR inhibitor-based combination therapies for pancreatic cancer
Hassan, Z., Schneeweis, C., Wirth, M., Veltkamp, C., Dantes, Z., Feuerecker, B., Ceyhan, G. O., Knauer, S. K., Weichert, W., Schmid, R. M., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.421 · Cited by 55
Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years
Hall, B. R., Cannon, A. C., Atri, P., Wichman, C., Smith, L. M., Ganti, A. K., Are, C., Sasson, A. R., Sushil Kumar, K., & Batra, S. K. (2018) · Oncotarget · doi:10.18632/oncotarget.25036 · Cited by 47
Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Tandon, M., Coudriet, G. M., Criscimanna, A., Socorro, M., Eliliwi, M., Singhi, A. D., Cruz‐Monserrate, Z., Bailey, P. J., Lotze, M. T., Zeh, H. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3064 · Cited by 50
“Among these classes, the squamous sub-type is an independent prognostic factor and is associated with poor outcomes (34).”
BackgroundInfluentialSelf-citationCamolotto, S. A., Belova, V. K., Torre-Healy, L. A., Vahrenkamp, J. M., Berrett, K. C., Conway, H., Shea, J., Stubben, C., Moffitt, R. A., Gertz, J., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321316 · Cited by 48
Frappart, P., & Hofmann, T. G. (2020) · Cancers · doi:10.3390/cancers12102750 · Cited by 59
“Gene expression-based profile studies using mainly resectable tumors, stratified PDAC into 3 (the “classical”, the “quasimesenchymal (QM)”, and the “exocrine-like”) [14] or 4 subtypes (the “squamous”, the “ADEX” (abnormally differentiated endocrine, exocrine), the “pancreatic progenitor”, and the “immunogenic”) [17].”
BackgroundKenney, C. M., Kunst, T. F., Webb, S., DeVisser, C., Arrowood, C., Steinberg, S. M., Mettu, N. B., Kim, E. J.-H., & Rudloff, U. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01044-8 · Cited by 48
Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence
Dreyer, S. B., Upstill‐Goddard, R., Legrini, A., Biankin, A. V., Allison, S. J., Biankin, A. V., Beraldi, D., Cameron, E. J., Chang, D. K., Cooke, S. L., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.09.022 · Cited by 54
Self-citationOncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Singh, H., Keller, R. B., Kapner, K. S., Dilly, J., Raghavan, S., Yuan, C., Cohen, E. F., Tolstorukov, M. Y., Andrews, E., Brais, L. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3930 · Cited by 58
Boelaars, K., Kruijssen, L. J. W., Wang, D., de Winde, C. M., Rodríguez, E., Lindijer, D., Springer, B. O., Àvila, I. V. D. H., de Haas, A. M., Wehry, L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007805 · Cited by 51
“47”
Next-generation therapies for pancreatic cancer
Buckley, C. W., & O'Reilly, E. M. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2322648 · Cited by 52
“In 2016, Waddell et al. performed further characterization via whole-genome, deep-exome sequencing, and RNA expression profiling, revealing four histopathological subtypes: squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine and exocrine (ADEX) [35].”
BackgroundWang, X., Wang, W., Zou, S., Xu, Z., Cao, D., Zhang, S., Wei, M., Zhan, Q., Wen, C., Li, F., et al. (2024) · Cell Research · doi:10.1038/s41422-024-00990-9 · Cited by 53
Moro, C. F., Fernandez-Woodbridge, A., D'souza, M. A., Zhang, Q., Bozóky, B., Vasan, S. K., Catalano, P., Heuchel, R. L., Shtembari, S., Chiaro, M. D., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166067 · Cited by 46
Exome-Wide Association Study of Pancreatic Cancer Risk
Grant, R. C., Denroche, R. E., Borgida, A., Virtanen, C., Cook, N., Smith, A. L., Connor, A. A., Wilson, J. M., Peterson, G., Roberts, N. J., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.10.015 · Cited by 51
Self-citationAdaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
Chen, P.-Y., Muzumdar, M. D., Dorans, K. J., Robbins, R., Bhutkar, A., del Rosario, A., Mertins, P., Qiao, J., Schafer, A. C., Gertler, F., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2129 · Cited by 46
“We used murine cells with defined genetic alterations frequently observed in human PDACs (Kras and p53) (6,35) to minimize genetic variability in our analyses.”
Stromal heterogeneity in pancreatic cancer and chronic pancreatitis
Häberle, L., Steiger, K., Schlitter, A. M., Safi, S. A., Knoefel, W. T., Erkan, M., & Esposito, I. (2018) · Pancreatology · doi:10.1016/j.pan.2018.05.004 · Cited by 48
Er, J. L., Goh, P. N., Lee, C. Y., Tan, Y. J., Hii, L., Mai, C., Chung, F. F., & Leong, C. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1459-6 · Cited by 50
Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer
Jain, A., Agostini, L. C., McCarthy, G. A., Chand, S. N., Ramirez, A., Nevler, A., Cozzitorto, J. A., Schultz, C. W., Lowder, C. Y., Smith, K. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3645 · Cited by 46
“In 2008, global genomic analyses on human pancreatic cancers revealed 12 core signaling pathways that were altered in the majority of PDAC [3-5],and subsequent sequencing studies have supported and expanded upon these initial findings [6, 7].”
Farran, B., & Nagaraju, G. P. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.07.001 · Cited by 49
Organoids from the Human Fetal and Adult Pancreas
Balak, J. R. A., Juksar, J., Carlotti, F., Nigro, A. L., & de Koning, E. J. P. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1261-z · Cited by 53
Klemke, L., Fehlau, C. F., Winkler, N., Toboll, F., Singh, S. K., Moll, U. M., & Schulz‐Heddergott, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642603 · Cited by 53
“Two datasets were used to detect mutated samples and the clinical data, QCMG, Nature 2016, and TCGA, PanCancer Atlas (41, 42).”
BackgroundMethodDatta, J., Bianchi, A., Silva, I. D. C., Deshpande, N., Cao, L., Mehra, S., Singh, S. P., Rafie, C. I., Sun, X., Chen, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02368-w · Cited by 46
“observed enrichment of the squamous molecular subtype [19] in KRAS-TP53 co-altered tumors compared with KRAS-altered/TP53 tumors in the TCGA-PAAD dataset (Fig.”
ResultSmall molecule inhibitors in pancreatic cancer
Sun, J., Russell, C. C., Scarlett, C. J., & McCluskey, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/c9md00447e · Cited by 46
Self-citationGroup Young Researchers in Inflammatory Carcinogenesis, Wandmacher, A. M., Mehdorn, A., & Sebens, S. (2021) · Cancers · doi:10.3390/cancers13194932 · Cited by 58
Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
Kung, H., & Yu, J. (2023) · MedComm · doi:10.1002/mco2.216 · Cited by 46
Guo, J., Wang, S., & Gao, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1258538 · Cited by 53
“In addition to these common mutations, there are less frequent mutated genes (-10% of tumors), including ARID1A, MLL3, and TGFBR2, which can contribute to a more aggressive phenotype of PDAC (11, 25).”
BackgroundInfluentialChimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence
Czaplicka, A., Lachota, M., Pączek, L., Zagożdżon, R., & Kaleta, B. (2024) · Cells · doi:10.3390/cells13010101 · Cited by 50
“Gene expression analyses allowed the identification of four molecular subtypes of PDAC with different biological traits and potential subtype-specific therapeutic options: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) [6].”
BackgroundSingh, S. P., Dosch, A. R., Mehra, S., Silva, I. D. C., Bianchi, A., Garrido, V. T., Zhou, Z., Adams, A. M., Amirian, H., Box, E. W., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1200 · Cited by 50
Papargyriou, A., Najajreh, M., Cook, D. P., Maurer, C. H., Bärthel, S., Messal, H. A., Ravichandran, S. K., Richter, T., Knolle, M. A., Metzler, T., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01273-9 · Cited by 57
“While numerous studies have identified distinct molecular PDAC subtypes on a transcriptional level 3,4 , it is likely that these subtypes are not static and present a continuum 5 .”
Klein, L., Tu, M., Krebs, N., Urbach, L., Grimm, D. T., Latif, M. U., Penz, F., Blandau, A., Wu, X., Samuel, R. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55330-7 · Cited by 56
“Lineage-speci fi c transcription factors (TFs) and epigenetic co-regulators are considered a key hallmark of PDAC subtype speci fi city and disease progression 4,21,25 – 28 .”
InfluentialPancreatic cancer stroma: controversies and current insights
Ansari, D., Carvajo, M., Bauden, M. P., & Andersson, R. E. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1293726 · Cited by 50
Panigrahi, P., Jere, A., & Anamika, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196588 · Cited by 46
Circulating Tumor DNA for Early Cancer Detection
Fiala, C., Kulasingam, V., & Diamandis, E. P. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.026393 · Cited by 46
Gendoo, D. M. A., Zon, M., Sandhu, V., Manem, V. S., Ratanasirigulchai, N., Chen, G. M., Waldron, L., & Haibe‐Kains, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-45165-4 · Cited by 45
Next-Generation Sequencing in Pancreatic Cancer
Shen, G.-Q., Aleassa, E. M., Walsh, R. M., & Morris‐Stiff, G. J. (2019) · Pancreas · doi:10.1097/mpa.0000000000001324 · Cited by 49
“Their results inferred differences in the molecular evolution of PDAC subtypes.(66) Waddell et al(67) performed WGS and copy number variation analysis in 100 patients with PDAC and in addition to genes known to be important in PDAC (TP53, SMAD4, CDKN2A, ARID1A, and ROBO2).”
ResultTherapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
Jin, M. H., Nam, A., Park, J. E., Bang, J., Bang, Y., & Oh, D. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.183 · Cited by 48
Sinn, M., Sinn, B. V., Treue, D., Keilholz, U., Damm, F., Schmuck, R. B., Lohneis, P., Klauschen, F., Striefler, J. K., Bahra, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3034 · Cited by 45
The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
García-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I., & Acedo, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040566 · Cited by 50
“Recent studies combining genetic and epigenetic sequencing have identified four distinct pancreatic cancer subtypes based on their molecular signatures (squamous, pancreatic progenitor, aberrantly differentiated endocrine exocrine or ADEX, and immunogenic) [7].”
BackgroundPancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells
Barman, S., Fatima, I., Singh, A. B., & Dhawan, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094765 · Cited by 47
Lu, W., Li, N., & Liao, F. (2019) · Genes · doi:10.3390/genes10080612 · Cited by 50
“This result may be explained by the fact that these patients were diagnosed as pancreatic cancer patients, and there must be a reason for the lack of clustering such as types of pancreatic adenocarcinoma, different disease subtypes and disease activity or disease stages [22].”
BackgroundLiu, X., Wang, W., Liu, X., Zhang, Z., Yu, L., Li, R., Guo, D., Cai, W., Quan, X., Wu, H., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.670 · Cited by 64
“45 SNVs called by Strelka2 were further filtered by the following criteria: (1) sequencing depth ≥20 at variant sites in both control and tumour samples; (2) ≤5 alternative reads support the variant in germline sample; (3)≥5 alternative reads support the variant in tumour sample Filtered variantswere then annotated by…”
MethodSkorupan, N., Ahmad, M. I., Steinberg, S. M., Trepel, J. B., Cridebring, D., Han, H., Hoff, D. D. V., & Alewine, C. (2022) · Future Oncology · doi:10.2217/fon-2021-1609 · Cited by 44
The Role of the Microbiome in Pancreatic Cancer
Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 53
“[58] identified an immunogenic subtype of cancer cells, which seems to be related to the immune-rich subtype of Maurer et al.”
BackgroundSanctis, F. D., Dusi, S., Caligola, S., Anselmi, C., Petrova, V., Rossi, B., Angelini, G., Erdeljan, M., Wöll, S., Schlitter, A. M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.04.021 · Cited by 47
“50 We replicated this analysis in published PDAC RNA-seq datasets, 17 but we could not confirm a similar correlation (data not shown).”
Self-citationPancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 65
“The classical and basal-like subtypes have been detected in multiple studies using samples from primary 119 – 121 and metastatic tumors.”
Fbxw7 Deletion Accelerates KrasG12D-Driven Pancreatic Tumorigenesis via Yap Accumulation
Zhang, Q., Zhang, Y., Parsels, J. D., Lohse, I., Lawrence, T. S., Pasca di Magliano, M., Sun, Y., & Morgan, M. A. (2016) · Neoplasia · doi:10.1016/j.neo.2016.08.009 · Cited by 44
“Although FBXW7 is most frequently mutated in colorectal, uterine, and bladder cancers, it is also a significantly mutated gene in pancreatic cancers [8,9].”
BackgroundShichino, S., Ueha, S., Hashimoto, S., Otsuji, M., Abe, J., Tsukui, T., Deshimaru, S., Nakajima, T., Kosugi‐Kanaya, M., Shand, F. H. W., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122163 · Cited by 47
“In particular, weighted coexpression network analysis (WGCNA) (11) is widely used to identify gene modules and centrally connected “hub” genes involved in a particular biological context, such as T cell exhaustion/memory (12), macrophage activation (13), neuronal differentiation (14), and pancreatic cancer (15).”
MethodFollia, L., Ferrero, G., Mandili, G., Beccuti, M., Giordano, D., Spadi, R., Satolli, M. A., Evangelista, A., Katayama, H., Hong, W., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00115 · Cited by 50
The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer
Hasan, N. M., & Ahuja, N. (2019) · Cancers · doi:10.3390/cancers11121859 · Cited by 56
“Percentages were calculated using data derived from the following studies: UTSW (109 samples, CNA and exome sequencing) [21], TCGA PanCan (184 samples, CNA and exome sequencing) [75–80], QCMG (383 samples, exome sequencing) [81], ICGC (99 samples, exome sequencing) [22] (percentages were color coded: blue-deep deletio…”
MethodJiang, M., Kang, Y., Sewastianik, T., Wang, J., Tanton, H., Alder, K., Dennis, P. S., Yu, X., Wang, Z., Liu, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13842-7 · Cited by 47
Kamyabi, N., Abbasgholizadeh, R., Maitra, A., Ardekani, A. M., Biswal, S. L., & Grande-Allen, K. J. (2020) · Biomedical Microdevices · doi:10.1007/s10544-020-00483-7 · Cited by 46
“(Kamisawa et al. 2016; Bailey et al. 2016) By coating two sets of devices with antibodies against either generic EVs surface proteins (CD63, CD9, and CD81) or a cancer-specific antigen (EpCAM) (Castillo et al. 2018), we were able to collect 10.3 ± 2.2 and 6.7 ± 1.7 ng DNA, respectively, from 2-ml…”
MethodInfluentialSelf-citation
Metadata
- Authors
- Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grützmann, R., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Initiative, A. P. C. G., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U.-M. H., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- Baylor College of Medicine (US)
- University of Utah (US)
- South Australia Pathology (AU)
- Harvard University (US)
- University of Glasgow (GB)
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- The University of Western Australia (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- NHS Greater Glasgow and Clyde (GB)
- Southern General Hospital (GB)
- Technische Universität Dresden (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- University of Verona (IT)
- Mayo Clinic (US)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Bailey, Peter
- Chang, David K.
- Johns, Amber L.
- Patch, Ann-Marie
- Gingras, Marie-Claude
- Christ, Angelika N.
- Quinn, Michael C.
- Murtaugh, L. Charles
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Holmes, Oliver
- Chin, Venessa
- Anderson, Matthew J.
- Kazakoff, Stephen
- Leonard, Conrad
- Newell, Felicity
- Wood, Scott
- Wilson, Peter J.
- Cloonan, Nicole
- Kassahn, Karin S.
- Quek, Kelly
- Robertson, Alan
- Pantano, Lorena
- Mincarelli, Laura
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Colvin, Emily K.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Mawson, Amanda
- Chou, Angela
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Toon, Christopher W.
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Oien, Karin
- Grützmann, Robert
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Bassi, Claudio
- Rusev, Borislav
- Salvia, Roberto
- Tortora, Giampaolo
- Petersen, Gloria M.
- Karim, Saadia A.
- Eshleman, James R.
- Hruban, Ralph H.
- Pilarsky, Christian
- Morton, Jennifer P.
- Sansom, Owen J.
- Scarpa, Aldo
- Bailey, Ulla-Maja Hagbo
- Hofmann, Oliver
- Wheeler, David A.
- Gill, Anthony J.
- Gibbs, Richard A.
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 531
- Issue
- 7592
- Pages
- 47-52
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2285093314
- Cited by
- 3,621
- References
- 52
- Citations by year
- 2026: 247 · 2025: 347 · 2024: 311 · 2023: 404 · 2022: 430 · 2021: 504 · 2020: 397 · 2019: 307 · 2018: 295 · 2017: 257 · 2016: 117
- FWCI
- 175.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (C29717/A17263, A12481, 17263, A18076, 12946, 20409, 11650, 21139, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, molecular subtypes, recurrent mutations, KRAS, TP53, p63, KDM6A, DNA methylation, pancreatic progenitor cells, endocrine differentiation, immunosuppression, prognosis, transcriptional regulatory networks, histopathology
- MeSH terms
- Homeobox Protein Nkx-2.2, Animals, DNA-Binding Proteins, Humans, Mutation, Nuclear Proteins, Pancreatic Neoplasms, Prognosis, Transcription Factors, Transcription, Genetic, Trans-Activators, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Analysis, Tumor Suppressor Protein p53, Receptors, Cytoplasmic and Nuclear, Homeodomain Proteins, DNA Methylation, Carcinoma, Pancreatic Ductal, Genomics, Tumor Suppressor Proteins, Zebrafish Proteins, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-beta, Hepatocyte Nuclear Factor 3-gamma, Basic Helix-Loop-Helix Proteins, Genes, Neoplasm, Gene Regulatory Networks, Histone Demethylases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.